Atorvastatin in OCD
Phase 4
- Conditions
- OCD.Obsessive-compulsive disorder
- Registration Number
- IRCT201511217290N2
- Lead Sponsor
- Deputy for Reaserch and Techonology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
resistant OCD (a patient should undergo continuous monotherapy treatment with SSRIs for three months in order to be defined as resistant); Signing inform consent.
Exclusion criteria: the patients did not have any innate neurological disorders, and laboratory test results for blood count; liver and renal functions were abnormal; a A minimum score of 21 in the Yale–Brown Scale (Y-BOCS) for OCD; breast feeding; pregnant women.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Yale brown Scale. Timepoint: 0 and 12th week after intervention. Method of measurement: Questionnaire completed by psychiatrist.
- Secondary Outcome Measures
Name Time Method Side effect. Timepoint: 0 and 12th week after intervention. Method of measurement: Patients' medical report.